EMEA-002931-PIP01-20

Key facts

Active substance
sabatolimab
Therapeutic area
Oncology
Decision number
P/0164/2021
PIP number
EMEA-002931-PIP01-20
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of myelodysplastic syndromes
Route(s) of administration
Intravenous use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613246715

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating